NextCure Q2 net loss $17.9M; cash $130.6M; Phase 1b data expected Q4 2023

NextCure, Inc.

2023-Q2 EPS reported -$1.22

Cash, cash equivalents and marketable securities of $130.6M as of June 30, 2023, down from $159.9M at Dec 31, 2022.
Net loss of $17.9M for Q2 2023, flat versus Q2 2022; R&D expense $13.4M, G&A $5.7M.
Phase 1b data for NC410, NC762 update, and NC525 Phase 1a update all expected in Q4 2023.
Existing cash expected to fund operations into mid-2025.
NC318 data from Yale Cancer Center to be presented at WCLC in September 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NextCure, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $17.9 million.

Period: quarter ended June 30, 2023
Net income: Net loss was $17.9 million
Result: reported results

Exact text from the filing

On August 3, 2023, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-013237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.